Etoposide (Vepesid)
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
Also known as
Abic Etoposide, Aside, Beposid, Bioposide, BO RUI, Bristol VP-16, Celltop, Citodox, Epocin, Eposid, Eposide, Eposido, Eposin, Epsidox, ETO, Etocris, Etomedac, Etonolver, Etopofos, Etopophos, Etopos, Etoposid, Etoposide Abic, Etoposid Ebewe, Etoposide Bigmar, Etoposide BVI, Etoposide Dakota, Etoposide DBL, Etoposide DUP, Etoposide Ebewe, Etoposide Eurocept, Etoposide Merck, Etoposide Pfizer, etoposide phosphate, Etoposide Teva, Etoposid Mayne, Etoposido, Etoposido Delta Farma, Etoposido Ferrer, Etoposido GI Kendr, Etoposido Servycal, Etoposido Varifarm, Etoposid Proreo, Etoposid Teva, Etopoxan, Etopul, Etosid, Etosin, Eunades CS, Euvaxon, Exitop, Fytop, Fytosid, HAI WEI LIN, Labimion, Lastet, Lastet S, Neoplaxol, Nexvep, Onkoposid, Optasid, P&U Etoposide, Percas, Posid, Posidon, Posyd, Riboposid, Sintopozid, Toposar, Toposide, Toposin, Topresid, Tosuben, Vepefos, Vepeside, Vepesid K, Vepesid S, Vepesid VP-16, Vepsid, Vepside, VP-16, VP-TEC, VP 16213
References
- Drug index
- Chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- Acute lymphocytic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Bone cancer medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Esophageal cancer medications
- Follicular lymphoma medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Transplant medications